Evommune (EVMN) Registration Filing summary

Company overview and business model

• Clinical-stage biotech focused on therapies for chronic inflammatory diseases, with lead programs in chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC).

• Pipeline includes two Phase 2 assets: EVO756 (oral MRGPRX2 antagonist) and EVO301 (injectable IL-18BP fusion protein).

• Management team has deep immunology and inflammation expertise, with a track record of successful drug development and commercialization.

• Business model includes internal R&D, in-licensing, and strategic collaborations, with a focus on high unmet need indications.

Financial performance and metrics

• Net loss of $66.8M in 2024 and $28.1M for the six months ended June 30, 2025; accumulated deficit of $180.3M as of June 30, 2025.

• Revenue of $7.0M in 2024 and $3.0M for the six months ended June 30, 2025, primarily from license agreements.

• R&D expenses were $64.2M in 2024 and $34.0M for the six months ended June 30, 2025; G&A expenses were $12.8M in 2024 and $7.0M for the six months ended June 30, 2025.

• Cash, cash equivalents, and short-term investments of $86.8M as of June 30, 2025.

Use of proceeds and capital allocation

• Net proceeds from the IPO will fund clinical development of EVO756 (Phase 2/3 in CSU and AD), Phase 2 development of EVO301 in AD, and additional R&D, business development, working capital, and general corporate purposes.

• May use a portion of proceeds for in-licensing, acquisitions, or investments in new businesses or technologies.